| Heading: |
Vamorolone |
| Question ID: |
1816037 |
| UIN: |
62450 |
| House: |
Commons |
| Date tabled: |
2025-06-24 |
| Asking Member ID: |
5296 |
| Asking Member display name: |
Freddie van Mierlo
|
| Asking Member handle: |
|
| Asking Member Twitter reference: |
Freddie van Mierlo
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, how many patients have accessed Vamorolone since it was given NICE approval for Duchenne Muscular Dystrophy; what assessment he has made of the adequacy of availability of Vamorolone to patients wi |
| Is named day: |
true |
| Date of holding answer: |
|
| Date answered: |
2025-06-30 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4444 |
| Answering Member display name: |
Karin Smyth
|
| Answering Member handle: |
karinsmyth
|
| Answering Member Twitter reference: |
@karinsmyth
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
The National Institute for Health and Care Excellence (NICE) published its technology appraisal, titled Vamorolone for treating Duchenne muscular dystrophy in people 4 years and over, on 16 January 2025. NHS England routinely commissioned vamorolone in li... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |